<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01899053</url>
  </required_header>
  <id_info>
    <org_study_id>C32001</org_study_id>
    <secondary_id>2013-000466-11</secondary_id>
    <nct_id>NCT01899053</nct_id>
  </id_info>
  <brief_title>A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies</brief_title>
  <official_title>A Multicenter, Open-label, Phase 1b Study of MLN0128 (an Oral mTORC1/2 Inhibitor) in Combination With MLN1117 (an Oral PI3KÎ± Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the safety and to determine dose-limiting
      toxicities (DLTs), maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and
      dosing schedules of oral TAK-228+TAK-117. It also evaluated the single- and multiple-dose
      plasma pharmacokinetics (PK) of TAK-228+TAK-117 in participants with advanced nonhematologic
      malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study was TAK-228. TAK-228 was tested to evaluate the safety,
      pharmacokinetics and efficacy, of TAK-228 in combination with TAK-117 when administered to
      adult participants with advanced nonhematologic malignancies.

      The study enrolled 101 patients. The study consisted of 2 phases: an escalation stage
      followed by an expansion stage. Participants in escalation stage were assigned to the
      following treatment arms:

        -  Dose escalation treatment arm A: TAK-228 2 or 4 mg capsule

        -  Dose escalation treatment arm B: TAK-228 3, 4, 6 or 8 mg capsule

        -  Dose escalation treatment arm C: TAK-228 3 mg capsule

      Upon completion of the escalation stage, 1 combination treatment regimen was selected for
      further safety, tolerability, pharmacokinetics, and mutual drug-drug interaction
      characterization in the expansion stage. During treatment, participants in both stages
      received TAK-228 and TAK-117 capsules at prespecified doses in repeated 28-day cycles.

      This multi-center trial conducted in the United States, United Kingdom and Spain. The overall
      time to participate in this study was approximately 68 weeks. Participants made multiple
      visits to the clinic, and a final visit after 30 days after last dose of study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2013</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">January 31, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>From Baseline to 30 days after the last dose of study drug (Up to approximately 68 weeks)</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above-mentioned criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time to Reach the Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</measure>
    <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</measure>
    <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</measure>
    <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</measure>
    <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</measure>
    <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>RAC: Accumulation Ratio for TAK-228 in the Dose Escalation Cohort</measure>
    <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
    <description>Accumulation ratio was based on AUC(0-24) between Cycle 1 Day 24 and Cycle 1 Day 1 (e.g. AUC(0-24) [Cycle 1 Day 24]/ AUC(0-24) [Cycle1 Day 1].</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak to Trough Ratio for TAK-228 After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</measure>
    <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation Cohort</measure>
    <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation Cohort</measure>
    <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort</measure>
    <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort</measure>
    <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort</measure>
    <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>RAC: Accumulation Ratio for TAK-117 in the Dose Escalation Cohort</measure>
    <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
    <description>Accumulation ratio was based on AUC(0-24) between Cycle 1 Day 24 and Cycle 1 Day 1 (e.g. AUC(0-24) [Cycle 1 Day 24]/ AUC(0-24) [Cycle1 Day 1].</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak to Trough Ratio After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort</measure>
    <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion Cohort</measure>
    <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion Cohort</measure>
    <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-228 in DDI Expansion Cohort</measure>
    <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Elimination Half-life (T1/2) for TAK-228 in DDI Expansion Cohort</measure>
    <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-228 in DDI Expansion Cohort</measure>
    <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak to Trough Ratio for TAK-228 in DDI Expansion Cohort</measure>
    <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion Cohort</measure>
    <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion Cohort</measure>
    <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-117 in DDI Expansion Cohort</measure>
    <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Elimination Half-life (T1/2) for TAK-117 in DDI Expansion Cohort</measure>
    <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-117 in DDI Expansion Cohort</measure>
    <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak to Trough Ratio for TAK-117 in DDI Expansion Cohort</measure>
    <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) Based on Investigator's Assessment According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</measure>
    <time_frame>Baseline, Days 22 up to Day 28 of Cycle and every even-numbered cycle until disease progression or EOS (Up to approximately 68 weeks)</time_frame>
    <description>ORR defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 for target lesions and assessed by CT or MRI. CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter (LD) of target lesions. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since the treatment started.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Baseline, Days 22 up to Day 28 of Cycle and every even-numbered cycle until disease progression or EOS (Up to approximately 68 weeks)</time_frame>
    <description>The DOR is defined as the time from the date of first documented response of CR/PR to the first documented progressive disease (PD), or censored at the last response assessment date that is SD or better for a participant that has not progressed. CR was defined as the disappearance of all target lesions and for non-target lesions, the disappearance of all non-target lesions and normalization of tumor marker level. PR was defined of at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Advanced Nonhematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Treatment Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-228 2 or 4 mg, capsule (milled or unmilled), orally, once daily every day (QD), and TAK-117 100, 200 or 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Treatment Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-228 3, 4, 6 or 8 mg, capsule (milled or unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 or 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to approximately 38.7 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Treatment Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-228 3 mg, capsule (milled or unmilled), orally, once on MTuW QW, and TAK-117 300 or 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to approximately 64.3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug-Drug Interaction (DDI) Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-228</intervention_name>
    <description>TAK-228 Capsules</description>
    <arm_group_label>Dose Escalation Treatment Arm A</arm_group_label>
    <arm_group_label>Dose Escalation Treatment Arm B</arm_group_label>
    <arm_group_label>Dose Escalation Treatment Arm C</arm_group_label>
    <arm_group_label>Drug-Drug Interaction (DDI) Expansion Cohort</arm_group_label>
    <other_name>MLN0128, INK128 or Sapanisertib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-117</intervention_name>
    <description>TAK-117 Capsules</description>
    <arm_group_label>Dose Escalation Treatment Arm A</arm_group_label>
    <arm_group_label>Dose Escalation Treatment Arm B</arm_group_label>
    <arm_group_label>Dose Escalation Treatment Arm C</arm_group_label>
    <arm_group_label>Drug-Drug Interaction (DDI) Expansion Cohort</arm_group_label>
    <other_name>MLN1117</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female participants 18 years or older

          -  Participants must have a diagnosis and documented disease progression of a solid tumor
             malignancy, excluding primary brain tumor, for which standard, curative, or life
             prolonging treatment does not exist or is no longer effective

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Female participants who are postmenopausal for at least 1 year prior to screening. For
             women of child-bearing potential agree to practice 2 effective methods of
             contraception or agree to practice true abstinence

          -  Male participants must agree to practice effective barrier contraception during the
             entire study treatment period and through 30 days after last dose of study drug or
             practice true abstinence

          -  Voluntary written consent

          -  Suitable venous access

          -  Participants must have a block of banked tumor tissue and/or fresh tumor tissue or at
             least 10 unstained slides available to be sent to the central laboratory

          -  Clinical laboratory values as specified in the protocol

          -  Participants must have radiographically or clinically evaluable tumor

        Exclusion Criteria:

          -  Female participants who are lactating and breastfeeding or have a positive serum
             pregnancy test during the Screening period or a positive urine pregnancy test on Day 1
             before first dose of study drug

          -  Any serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with the completion of treatment

          -  Treatment with any investigational products within 30 days before the first dose of
             study drug

          -  Previous treatment with TAK-117 and/or TAK-228; previous treatment with dual mTORC1/2
             or dual PI3K-mTOR inhibitors

          -  Failed to have recovered from the reversible effects of previous anticancer therapies

          -  Have received systemic corticosteroid (inhalers are allowed) within 7 days before the
             first administration of study drug

          -  Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral
             absorption or tolerance of study drug

          -  Diagnosis of diabetes mellitus

          -  Other clinically significant co-morbidities, such as uncontrolled pulmonary disease,
             active CNS disease, active infection

          -  Known human immunodeficiency virus (HIV) infection

          -  Cardiovascular conditions as defined in the protocol

          -  A requirement for positive inotropic support (excluding digoxin) or serious
             uncontrolled cardiac arrhythmia (including atrial flutter/fibrillation) within 1 year
             before screening

          -  Participants who are taking proton pump inhibitors within 7 days of the first dose or
             who require treatment with proton pump inhibitors during the trial or those who are
             taking histamine-2 (H2) receptor antagonists within 24 hours of the first dose

          -  Participants who received previous therapy with PI3K inhibitors or rapalogs will be
             allowed in the study if all other inclusion/exclusion criteria are met

          -  Diagnosis of primary brain tumor or symptomatic brain metastasis. Participants with
             brain metastases must be without neurologic dysfunction that would confound the
             evaluation of neurologic and other adverse events (AEs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ejcancer.com/article/S0959-8049(16)32625-9/abstract</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>July 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2013</study_first_posted>
  <results_first_submitted>April 26, 2019</results_first_submitted>
  <results_first_submitted_qc>October 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2019</results_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <keyword>TAK-228</keyword>
  <keyword>TAK-117</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Serabelisib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT01899053/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT01899053/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 5 investigative sites in Spain, United Kingdom and United States from 28 June 2013 to 30 April 2018.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of advanced nonhematologic malignancies were enrolled. A total of 101 participants were enrolled, out of which 81 entered the escalation phase, and 20 entered the expansion phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
          <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
          <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
          <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
          <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
          <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
          <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
          <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
        </group>
        <group group_id="P8">
          <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
          <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
        </group>
        <group group_id="P9">
          <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
          <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
        </group>
        <group group_id="P10">
          <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
          <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
        </group>
        <group group_id="P11">
          <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
          <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
        </group>
        <group group_id="P12">
          <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
          <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
        </group>
        <group group_id="P13">
          <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
          <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
        </group>
        <group group_id="P14">
          <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled)</title>
          <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="16"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="14"/>
                <participants group_id="P14" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="16"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="14"/>
                <participants group_id="P14" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="8"/>
                <participants group_id="P14" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory Therapeutic Response</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Symptomatic Deterioration</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population consisted of all enrolled participants who received at least 1 dose of any study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
          <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
          <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
          <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
          <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
          <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
          <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
          <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
          <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
        </group>
        <group group_id="B9">
          <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
          <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
        </group>
        <group group_id="B10">
          <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
          <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
        </group>
        <group group_id="B11">
          <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
          <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
        </group>
        <group group_id="B12">
          <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
          <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
        </group>
        <group group_id="B13">
          <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
          <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
        </group>
        <group group_id="B14">
          <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled)</title>
          <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
        </group>
        <group group_id="B15">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="3"/>
            <count group_id="B7" value="3"/>
            <count group_id="B8" value="3"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="3"/>
            <count group_id="B11" value="16"/>
            <count group_id="B12" value="7"/>
            <count group_id="B13" value="14"/>
            <count group_id="B14" value="20"/>
            <count group_id="B15" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.9" spread="6.31"/>
                    <measurement group_id="B2" value="69.3" spread="5.13"/>
                    <measurement group_id="B3" value="50.6" spread="14.05"/>
                    <measurement group_id="B4" value="66.7" spread="5.86"/>
                    <measurement group_id="B5" value="48.7" spread="11.66"/>
                    <measurement group_id="B6" value="74.3" spread="5.13"/>
                    <measurement group_id="B7" value="69.3" spread="14.15"/>
                    <measurement group_id="B8" value="68.3" spread="9.24"/>
                    <measurement group_id="B9" value="58.0" spread="7.72"/>
                    <measurement group_id="B10" value="68.3" spread="4.16"/>
                    <measurement group_id="B11" value="56.6" spread="9.69"/>
                    <measurement group_id="B12" value="53.3" spread="14.36"/>
                    <measurement group_id="B13" value="56.5" spread="6.97"/>
                    <measurement group_id="B14" value="63.4" spread="9.10"/>
                    <measurement group_id="B15" value="59.4" spread="10.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="11"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="7"/>
                    <measurement group_id="B14" value="13"/>
                    <measurement group_id="B15" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="7"/>
                    <measurement group_id="B14" value="7"/>
                    <measurement group_id="B15" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="13"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="13"/>
                    <measurement group_id="B14" value="9"/>
                    <measurement group_id="B15" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="7"/>
                    <measurement group_id="B15" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="13"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="14"/>
                    <measurement group_id="B14" value="19"/>
                    <measurement group_id="B15" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black Or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="12"/>
                    <measurement group_id="B15" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="7"/>
                    <measurement group_id="B15" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164.0" spread="3.84"/>
                    <measurement group_id="B2" value="165.1" spread="5.08"/>
                    <measurement group_id="B3" value="161.6" spread="3.26"/>
                    <measurement group_id="B4" value="159.4" spread="7.73"/>
                    <measurement group_id="B5" value="169.8" spread="8.73"/>
                    <measurement group_id="B6" value="169.0" spread="12.86"/>
                    <measurement group_id="B7" value="157.3" spread="4.25"/>
                    <measurement group_id="B8" value="168.5" spread="15.02"/>
                    <measurement group_id="B9" value="168.3" spread="12.41"/>
                    <measurement group_id="B10" value="168.5" spread="8.30"/>
                    <measurement group_id="B11" value="168.7" spread="11.24"/>
                    <measurement group_id="B12" value="180.7" spread="9.35"/>
                    <measurement group_id="B13" value="170.7" spread="7.86"/>
                    <measurement group_id="B14" value="163.7" spread="7.64"/>
                    <measurement group_id="B15" value="167.3" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.8" spread="9.11"/>
                    <measurement group_id="B2" value="78.4" spread="1.34"/>
                    <measurement group_id="B3" value="69.7" spread="14.20"/>
                    <measurement group_id="B4" value="49.8" spread="8.06"/>
                    <measurement group_id="B5" value="79.5" spread="19.91"/>
                    <measurement group_id="B6" value="67.6" spread="20.33"/>
                    <measurement group_id="B7" value="62.5" spread="15.32"/>
                    <measurement group_id="B8" value="73.7" spread="17.32"/>
                    <measurement group_id="B9" value="78.2" spread="22.65"/>
                    <measurement group_id="B10" value="79.3" spread="9.11"/>
                    <measurement group_id="B11" value="71.4" spread="13.00"/>
                    <measurement group_id="B12" value="79.9" spread="15.19"/>
                    <measurement group_id="B13" value="78.6" spread="17.55"/>
                    <measurement group_id="B14" value="64.6" spread="12.08"/>
                    <measurement group_id="B15" value="71.4" spread="15.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI was calculated as weight/[height^2].</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.7" spread="2.80"/>
                    <measurement group_id="B2" value="28.8" spread="2.09"/>
                    <measurement group_id="B3" value="26.7" spread="5.65"/>
                    <measurement group_id="B4" value="19.9" spread="5.06"/>
                    <measurement group_id="B5" value="27.3" spread="5.09"/>
                    <measurement group_id="B6" value="23.2" spread="3.36"/>
                    <measurement group_id="B7" value="25.4" spread="7.18"/>
                    <measurement group_id="B8" value="26.2" spread="6.76"/>
                    <measurement group_id="B9" value="27.2" spread="4.60"/>
                    <measurement group_id="B10" value="27.9" spread="3.11"/>
                    <measurement group_id="B11" value="25.2" spread="4.30"/>
                    <measurement group_id="B12" value="24.3" spread="3.27"/>
                    <measurement group_id="B13" value="27.0" spread="5.74"/>
                    <measurement group_id="B14" value="24.1" spread="4.06"/>
                    <measurement group_id="B15" value="25.4" spread="4.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)</title>
        <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above-mentioned criteria.</description>
        <time_frame>From Baseline to 30 days after the last dose of study drug (Up to approximately 68 weeks)</time_frame>
        <population>Safety population consisted of all enrolled participants who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
            <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
            <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
            <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
            <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
            <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
            <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
          </group>
          <group group_id="O14">
            <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)</title>
          <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above-mentioned criteria.</description>
          <population>Safety population consisted of all enrolled participants who received at least 1 dose of any study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="14"/>
                <count group_id="O14" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="16"/>
                    <measurement group_id="O12" value="7"/>
                    <measurement group_id="O13" value="14"/>
                    <measurement group_id="O14" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time to Reach the Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</title>
        <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>Pharmacokinetic (PK) population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
            <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
            <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
            <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
            <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
            <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
            <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</title>
          <population>Pharmacokinetic (PK) population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="16"/>
                    <count group_id="O12" value="6"/>
                    <count group_id="O13" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O2" value="1.000" lower_limit="0.97" upper_limit="1.03"/>
                    <measurement group_id="O3" value="1.000" lower_limit="0.50" upper_limit="4.07"/>
                    <measurement group_id="O4" value="2.050" lower_limit="0.53" upper_limit="2.07"/>
                    <measurement group_id="O5" value="1.033" lower_limit="1.00" upper_limit="2.08"/>
                    <measurement group_id="O6" value="2.083" lower_limit="1.97" upper_limit="4.02"/>
                    <measurement group_id="O7" value="1.000" lower_limit="0.48" upper_limit="1.07"/>
                    <measurement group_id="O8" value="1.067" lower_limit="1.03" upper_limit="8.12"/>
                    <measurement group_id="O9" value="1.358" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O10" value="1.067" lower_limit="0.98" upper_limit="3.83"/>
                    <measurement group_id="O11" value="1.000" lower_limit="0.50" upper_limit="2.15"/>
                    <measurement group_id="O12" value="0.725" lower_limit="0.43" upper_limit="2.08"/>
                    <measurement group_id="O13" value="0.983" lower_limit="0.47" upper_limit="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="9"/>
                    <count group_id="O12" value="4"/>
                    <count group_id="O13" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O2" value="0.758" lower_limit="0.48" upper_limit="1.03"/>
                    <measurement group_id="O3" value="1.400" lower_limit="0.45" upper_limit="4.08"/>
                    <measurement group_id="O5" value="2.000" lower_limit="0.92" upper_limit="2.25"/>
                    <measurement group_id="O6" value="4.000" lower_limit="1.00" upper_limit="4.12"/>
                    <measurement group_id="O7" value="1.408" lower_limit="1.00" upper_limit="1.82"/>
                    <measurement group_id="O8" value="0.617" lower_limit="0.48" upper_limit="2.00"/>
                    <measurement group_id="O9" value="0.925" lower_limit="0.50" upper_limit="2.15"/>
                    <measurement group_id="O10" value="4.000" lower_limit="4.000" upper_limit="4.000"/>
                    <measurement group_id="O11" value="1.033" lower_limit="0.47" upper_limit="2.30"/>
                    <measurement group_id="O12" value="2.083" lower_limit="1.95" upper_limit="4.87"/>
                    <measurement group_id="O13" value="1.017" lower_limit="0.50" upper_limit="7.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</title>
        <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
            <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
            <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
            <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
            <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
            <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
            <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</title>
          <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="16"/>
                    <count group_id="O12" value="6"/>
                    <count group_id="O13" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.63" spread="7.355"/>
                    <measurement group_id="O2" value="39.73" spread="7.853"/>
                    <measurement group_id="O3" value="25.80" spread="8.188"/>
                    <measurement group_id="O4" value="28.67" spread="3.702"/>
                    <measurement group_id="O5" value="18.26" spread="8.610"/>
                    <measurement group_id="O6" value="21.69" spread="29.273"/>
                    <measurement group_id="O7" value="48.90" spread="28.157"/>
                    <measurement group_id="O8" value="33.30" spread="16.301"/>
                    <measurement group_id="O9" value="53.10" spread="7.257"/>
                    <measurement group_id="O10" value="53.53" spread="29.788"/>
                    <measurement group_id="O11" value="42.17" spread="11.495"/>
                    <measurement group_id="O12" value="27.53" spread="11.665"/>
                    <measurement group_id="O13" value="26.51" spread="12.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="9"/>
                    <count group_id="O12" value="4"/>
                    <count group_id="O13" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.78" spread="6.632"/>
                    <measurement group_id="O2" value="53.55" spread="2.192"/>
                    <measurement group_id="O3" value="29.45" spread="9.746"/>
                    <measurement group_id="O5" value="13.75" spread="6.938"/>
                    <measurement group_id="O6" value="37.36" spread="49.078"/>
                    <measurement group_id="O7" value="46.10" spread="17.253"/>
                    <measurement group_id="O8" value="72.43" spread="13.094"/>
                    <measurement group_id="O9" value="61.58" spread="14.894"/>
                    <measurement group_id="O10" value="17.1" spread="0"/>
                    <measurement group_id="O11" value="50.68" spread="12.055"/>
                    <measurement group_id="O12" value="17.75" spread="4.865"/>
                    <measurement group_id="O13" value="35.59" spread="18.415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</title>
        <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
            <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
            <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
            <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
            <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
            <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
            <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</title>
          <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="16"/>
                    <count group_id="O12" value="6"/>
                    <count group_id="O13" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.888" spread="36.1184"/>
                    <measurement group_id="O2" value="247.361" spread="156.0211"/>
                    <measurement group_id="O3" value="138.929" spread="37.3727"/>
                    <measurement group_id="O4" value="230.983" spread="14.6292"/>
                    <measurement group_id="O5" value="109.622" spread="45.6613"/>
                    <measurement group_id="O6" value="126.062" spread="120.8204"/>
                    <measurement group_id="O7" value="303.897" spread="152.5659"/>
                    <measurement group_id="O8" value="287.283" spread="268.7088"/>
                    <measurement group_id="O9" value="351.602" spread="122.6407"/>
                    <measurement group_id="O10" value="382.588" spread="250.2623"/>
                    <measurement group_id="O11" value="249.341" spread="128.4868"/>
                    <measurement group_id="O12" value="168.408" spread="103.9245"/>
                    <measurement group_id="O13" value="160.670" spread="90.6815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="9"/>
                    <count group_id="O12" value="4"/>
                    <count group_id="O13" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.418" spread="169.5373"/>
                    <measurement group_id="O2" value="208.389" spread="78.6461"/>
                    <measurement group_id="O3" value="200.762" spread="56.1368"/>
                    <measurement group_id="O5" value="115.884" spread="50.7913"/>
                    <measurement group_id="O6" value="203.836" spread="120.1336"/>
                    <measurement group_id="O7" value="410.604" spread="265.8768"/>
                    <measurement group_id="O8" value="535.365" spread="256.8762"/>
                    <measurement group_id="O9" value="331.286" spread="133.7879"/>
                    <measurement group_id="O10" value="305.97" spread="0"/>
                    <measurement group_id="O11" value="317.111" spread="151.6045"/>
                    <measurement group_id="O12" value="132.058" spread="71.7154"/>
                    <measurement group_id="O13" value="211.792" spread="100.9091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</title>
        <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
            <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
            <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
            <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
            <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
            <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
            <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</title>
          <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="2"/>
                    <count group_id="O11" value="14"/>
                    <count group_id="O12" value="6"/>
                    <count group_id="O13" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.090" spread="2.1653"/>
                    <measurement group_id="O2" value="5.783" spread="3.3941"/>
                    <measurement group_id="O3" value="6.214" spread="2.6649"/>
                    <measurement group_id="O4" value="7.450" spread="0.7368"/>
                    <measurement group_id="O5" value="6.975" spread="1.0108"/>
                    <measurement group_id="O6" value="4.65" spread="0"/>
                    <measurement group_id="O7" value="8.412" spread="1.3996"/>
                    <measurement group_id="O8" value="4.96" spread="0"/>
                    <measurement group_id="O9" value="5.792" spread="3.4405"/>
                    <measurement group_id="O10" value="6.799" spread="5.5740"/>
                    <measurement group_id="O11" value="6.320" spread="1.7839"/>
                    <measurement group_id="O12" value="5.512" spread="2.1598"/>
                    <measurement group_id="O13" value="7.593" spread="1.1365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="8"/>
                    <count group_id="O12" value="1"/>
                    <count group_id="O13" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.489" spread="2.4782"/>
                    <measurement group_id="O2" value="4.686" spread="2.1265"/>
                    <measurement group_id="O3" value="5.521" spread="1.6417"/>
                    <measurement group_id="O5" value="7.635" spread="1.1253"/>
                    <measurement group_id="O6" value="5.43" spread="0"/>
                    <measurement group_id="O7" value="8.5" spread="0"/>
                    <measurement group_id="O8" value="6.808" spread="1.7326"/>
                    <measurement group_id="O9" value="6.221" spread="1.0591"/>
                    <measurement group_id="O11" value="5.940" spread="1.6737"/>
                    <measurement group_id="O12" value="6.42" spread="0"/>
                    <measurement group_id="O13" value="6.354" spread="1.9320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</title>
        <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK population consisted of all participants enrolled during the dose escalation and expansion stage of the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants who were evaluable at each category.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
            <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
            <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
            <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
            <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
            <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
            <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</title>
          <population>PK population consisted of all participants enrolled during the dose escalation and expansion stage of the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants who were evaluable at each category.</population>
          <units>L/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="2"/>
                    <count group_id="O11" value="14"/>
                    <count group_id="O12" value="6"/>
                    <count group_id="O13" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.534" spread="5.4762"/>
                    <measurement group_id="O2" value="19.049" spread="11.8558"/>
                    <measurement group_id="O3" value="14.419" spread="7.5636"/>
                    <measurement group_id="O4" value="7.694" spread="0.5750"/>
                    <measurement group_id="O5" value="15.311" spread="3.6762"/>
                    <measurement group_id="O6" value="11.38" spread="0"/>
                    <measurement group_id="O7" value="10.728" spread="6.9669"/>
                    <measurement group_id="O8" value="28.54" spread="0"/>
                    <measurement group_id="O9" value="19.999" spread="10.0509"/>
                    <measurement group_id="O10" value="16.259" spread="9.3725"/>
                    <measurement group_id="O11" value="17.924" spread="9.5261"/>
                    <measurement group_id="O12" value="22.715" spread="14.7252"/>
                    <measurement group_id="O13" value="13.933" spread="5.4880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="8"/>
                    <count group_id="O12" value="1"/>
                    <count group_id="O13" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.720" spread="4.5824"/>
                    <measurement group_id="O2" value="18.207" spread="4.1819"/>
                    <measurement group_id="O3" value="10.597" spread="3.9917"/>
                    <measurement group_id="O5" value="15.683" spread="2.9149"/>
                    <measurement group_id="O6" value="9.23" spread="0"/>
                    <measurement group_id="O7" value="13.58" spread="0"/>
                    <measurement group_id="O8" value="12.817" spread="4.7929"/>
                    <measurement group_id="O9" value="19.060" spread="7.1913"/>
                    <measurement group_id="O11" value="14.196" spread="5.3137"/>
                    <measurement group_id="O12" value="15.53" spread="0"/>
                    <measurement group_id="O13" value="16.133" spread="8.6701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>RAC: Accumulation Ratio for TAK-228 in the Dose Escalation Cohort</title>
        <description>Accumulation ratio was based on AUC(0-24) between Cycle 1 Day 24 and Cycle 1 Day 1 (e.g. AUC(0-24) [Cycle 1 Day 24]/ AUC(0-24) [Cycle1 Day 1].</description>
        <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Overall number of participants analyzed is the number of participants with evaluable data at both Days 1 and 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
            <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
            <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
            <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
            <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
            <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
            <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>RAC: Accumulation Ratio for TAK-228 in the Dose Escalation Cohort</title>
          <description>Accumulation ratio was based on AUC(0-24) between Cycle 1 Day 24 and Cycle 1 Day 1 (e.g. AUC(0-24) [Cycle 1 Day 24]/ AUC(0-24) [Cycle1 Day 1].</description>
          <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Overall number of participants analyzed is the number of participants with evaluable data at both Days 1 and 24.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="1"/>
                <count group_id="O11" value="8"/>
                <count group_id="O12" value="2"/>
                <count group_id="O13" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.225" spread="1.4576"/>
                    <measurement group_id="O2" value="1.25" spread="0"/>
                    <measurement group_id="O3" value="1.495" spread="0.1884"/>
                    <measurement group_id="O5" value="1.219" spread="0.3497"/>
                    <measurement group_id="O6" value="1.569" spread="0.4099"/>
                    <measurement group_id="O7" value="1.712" spread="0.2650"/>
                    <measurement group_id="O8" value="1.718" spread="0.4329"/>
                    <measurement group_id="O9" value="1.015" spread="0.1453"/>
                    <measurement group_id="O10" value="1.58" spread="0"/>
                    <measurement group_id="O11" value="1.172" spread="0.3363"/>
                    <measurement group_id="O12" value="1.213" spread="0.1306"/>
                    <measurement group_id="O13" value="1.461" spread="0.2246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak to Trough Ratio for TAK-228 After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</title>
        <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
            <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
            <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
            <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
            <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
            <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
            <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak to Trough Ratio for TAK-228 After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort</title>
          <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="5"/>
                    <count group_id="O10" value="2"/>
                    <count group_id="O11" value="14"/>
                    <count group_id="O12" value="4"/>
                    <count group_id="O13" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.546" spread="6.5659"/>
                    <measurement group_id="O2" value="13.588" spread="8.3649"/>
                    <measurement group_id="O3" value="14.553" spread="6.8807"/>
                    <measurement group_id="O4" value="10.420" spread="1.5662"/>
                    <measurement group_id="O5" value="13.983" spread="6.6782"/>
                    <measurement group_id="O6" value="23.757" spread="31.1525"/>
                    <measurement group_id="O7" value="14.336" spread="7.0986"/>
                    <measurement group_id="O8" value="20.212" spread="22.0357"/>
                    <measurement group_id="O9" value="13.227" spread="8.3834"/>
                    <measurement group_id="O10" value="5.761" spread="1.5250"/>
                    <measurement group_id="O11" value="22.676" spread="14.2142"/>
                    <measurement group_id="O12" value="15.012" spread="6.5253"/>
                    <measurement group_id="O13" value="10.725" spread="2.7876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="8"/>
                    <count group_id="O12" value="2"/>
                    <count group_id="O13" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.145" spread="6.0465"/>
                    <measurement group_id="O2" value="27.66" spread="0"/>
                    <measurement group_id="O3" value="14.691" spread="8.1076"/>
                    <measurement group_id="O5" value="9.363" spread="6.6336"/>
                    <measurement group_id="O6" value="21.864" spread="33.1541"/>
                    <measurement group_id="O7" value="9.305" spread="4.7969"/>
                    <measurement group_id="O8" value="21.979" spread="13.7911"/>
                    <measurement group_id="O9" value="31.971" spread="19.6410"/>
                    <measurement group_id="O10" value="1.8" spread="0"/>
                    <measurement group_id="O11" value="22.555" spread="10.4006"/>
                    <measurement group_id="O12" value="8.805" spread="7.3805"/>
                    <measurement group_id="O13" value="21.157" spread="14.9668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation Cohort</title>
        <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
            <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
            <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
            <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
            <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
            <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
            <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation Cohort</title>
          <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="16"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.800" lower_limit="0.50" upper_limit="2.03"/>
                    <measurement group_id="O2" value="2.000" lower_limit="1.03" upper_limit="2.00"/>
                    <measurement group_id="O3" value="2.050" lower_limit="0.52" upper_limit="4.08"/>
                    <measurement group_id="O4" value="2.050" lower_limit="1.03" upper_limit="2.07"/>
                    <measurement group_id="O5" value="3.017" lower_limit="1.85" upper_limit="7.50"/>
                    <measurement group_id="O6" value="1.97" lower_limit="1.97" upper_limit="1.97"/>
                    <measurement group_id="O7" value="2.000" lower_limit="1.07" upper_limit="4.18"/>
                    <measurement group_id="O8" value="1.033" lower_limit="0.50" upper_limit="8.12"/>
                    <measurement group_id="O9" value="4.008" lower_limit="0.50" upper_limit="7.25"/>
                    <measurement group_id="O10" value="3.883" lower_limit="2.42" upper_limit="7.33"/>
                    <measurement group_id="O11" value="1.925" lower_limit="1.00" upper_limit="4.15"/>
                    <measurement group_id="O12" value="2.083" lower_limit="0.95" upper_limit="6.03"/>
                    <measurement group_id="O13" value="3.125" lower_limit="0.50" upper_limit="22.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="9"/>
                    <count group_id="O12" value="4"/>
                    <count group_id="O13" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.55" upper_limit="4.00"/>
                    <measurement group_id="O2" value="1.025" lower_limit="1.02" upper_limit="1.03"/>
                    <measurement group_id="O3" value="4.108" lower_limit="0.93" upper_limit="8.02"/>
                    <measurement group_id="O5" value="2.417" lower_limit="1.97" upper_limit="4.00"/>
                    <measurement group_id="O6" value="2.000" lower_limit="1.92" upper_limit="4.00"/>
                    <measurement group_id="O7" value="1.408" lower_limit="1.00" upper_limit="1.82"/>
                    <measurement group_id="O8" value="0.883" lower_limit="0.62" upper_limit="4.05"/>
                    <measurement group_id="O9" value="3.150" lower_limit="2.00" upper_limit="7.02"/>
                    <measurement group_id="O10" value="7.33" lower_limit="7.33" upper_limit="7.33"/>
                    <measurement group_id="O11" value="2.000" lower_limit="1.00" upper_limit="8.02"/>
                    <measurement group_id="O12" value="2.050" lower_limit="1.40" upper_limit="4.27"/>
                    <measurement group_id="O13" value="1.117" lower_limit="0.95" upper_limit="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation Cohort</title>
        <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
            <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
            <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
            <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
            <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
            <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
            <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation Cohort</title>
          <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="16"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1800.0" spread="1049.25"/>
                    <measurement group_id="O2" value="988.7" spread="858.57"/>
                    <measurement group_id="O3" value="3067.1" spread="1243.50"/>
                    <measurement group_id="O4" value="4950.0" spread="3381.06"/>
                    <measurement group_id="O5" value="4136.7" spread="1487.68"/>
                    <measurement group_id="O6" value="2420" spread="0"/>
                    <measurement group_id="O7" value="3836.7" spread="656.07"/>
                    <measurement group_id="O8" value="1631.3" spread="1305.25"/>
                    <measurement group_id="O9" value="2711.7" spread="1172.97"/>
                    <measurement group_id="O10" value="2568.7" spread="2107.04"/>
                    <measurement group_id="O11" value="3369.4" spread="1417.31"/>
                    <measurement group_id="O12" value="3077.7" spread="1629.05"/>
                    <measurement group_id="O13" value="3353.0" spread="1955.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="9"/>
                    <count group_id="O12" value="4"/>
                    <count group_id="O13" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2514.0" spread="1597.13"/>
                    <measurement group_id="O2" value="2720.0" spread="1286.93"/>
                    <measurement group_id="O3" value="3438.3" spread="1687.00"/>
                    <measurement group_id="O5" value="3624.0" spread="2925.79"/>
                    <measurement group_id="O6" value="1054.8" spread="1454.94"/>
                    <measurement group_id="O7" value="6180.0" spread="127.28"/>
                    <measurement group_id="O8" value="4876.7" spread="848.84"/>
                    <measurement group_id="O9" value="4477.5" spread="953.88"/>
                    <measurement group_id="O10" value="100" spread="0"/>
                    <measurement group_id="O11" value="4863.3" spread="1142.54"/>
                    <measurement group_id="O12" value="3755.0" spread="2831.78"/>
                    <measurement group_id="O13" value="4805.3" spread="2893.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort</title>
        <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
            <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
            <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
            <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
            <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
            <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
            <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort</title>
          <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="16"/>
                    <count group_id="O12" value="7"/>
                    <count group_id="O13" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14586.139" spread="10434.5445"/>
                    <measurement group_id="O2" value="11550.908" spread="11672.0852"/>
                    <measurement group_id="O3" value="43948.190" spread="25421.3428"/>
                    <measurement group_id="O4" value="69617.994" spread="46233.0898"/>
                    <measurement group_id="O5" value="54993.211" spread="27446.4517"/>
                    <measurement group_id="O6" value="26746.78" spread="0"/>
                    <measurement group_id="O7" value="47803.262" spread="4758.7418"/>
                    <measurement group_id="O8" value="23148.610" spread="27836.8878"/>
                    <measurement group_id="O9" value="38563.109" spread="23484.8077"/>
                    <measurement group_id="O10" value="39903.517" spread="33243.1212"/>
                    <measurement group_id="O11" value="38224.835" spread="22368.0163"/>
                    <measurement group_id="O12" value="30925.255" spread="15126.4913"/>
                    <measurement group_id="O13" value="46451.606" spread="33137.8861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="9"/>
                    <count group_id="O12" value="4"/>
                    <count group_id="O13" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31723.844" spread="38363.4872"/>
                    <measurement group_id="O2" value="22566.251" spread="13562.8900"/>
                    <measurement group_id="O3" value="50960.181" spread="32295.5320"/>
                    <measurement group_id="O5" value="46278.615" spread="48171.7982"/>
                    <measurement group_id="O6" value="12428.783" spread="16745.7861"/>
                    <measurement group_id="O7" value="90462.795" spread="14090.4676"/>
                    <measurement group_id="O8" value="67186.097" spread="49493.0584"/>
                    <measurement group_id="O9" value="55908.919" spread="39888.9699"/>
                    <measurement group_id="O10" value="1674.23" spread="0"/>
                    <measurement group_id="O11" value="72432.560" spread="27615.6802"/>
                    <measurement group_id="O12" value="46164.679" spread="37938.0208"/>
                    <measurement group_id="O13" value="70490.572" spread="58515.7794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort</title>
        <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
            <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
            <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
            <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
            <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
            <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
            <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort</title>
          <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="2"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="4"/>
                    <count group_id="O12" value="3"/>
                    <count group_id="O13" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.590" spread="3.4673"/>
                    <measurement group_id="O2" value="4.92" spread="0"/>
                    <measurement group_id="O8" value="3.839" spread="3.5498"/>
                    <measurement group_id="O9" value="7.465" spread="2.2023"/>
                    <measurement group_id="O11" value="4.858" spread="2.7928"/>
                    <measurement group_id="O12" value="6.379" spread="1.5369"/>
                    <measurement group_id="O13" value="7.368" spread="0.3774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="2"/>
                    <count group_id="O13" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.722" spread="3.1259"/>
                    <measurement group_id="O2" value="6.53" spread="0"/>
                    <measurement group_id="O3" value="2.98" spread="0"/>
                    <measurement group_id="O5" value="3.2" spread="0"/>
                    <measurement group_id="O6" value="8.37" spread="0"/>
                    <measurement group_id="O8" value="6.233" spread="4.4813"/>
                    <measurement group_id="O9" value="4.61" spread="0"/>
                    <measurement group_id="O11" value="7.717" spread="2.6428"/>
                    <measurement group_id="O12" value="5.853" spread="2.1534"/>
                    <measurement group_id="O13" value="5.984" spread="3.6558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort</title>
        <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
            <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
            <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
            <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
            <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
            <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
            <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort</title>
          <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="2"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="4"/>
                    <count group_id="O12" value="3"/>
                    <count group_id="O13" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.993" spread="23.6496"/>
                    <measurement group_id="O2" value="9.79" spread="0"/>
                    <measurement group_id="O8" value="194.998" spread="258.2751"/>
                    <measurement group_id="O9" value="20.944" spread="16.6625"/>
                    <measurement group_id="O11" value="17.879" spread="17.8072"/>
                    <measurement group_id="O12" value="21.075" spread="16.4116"/>
                    <measurement group_id="O13" value="32.455" spread="35.8687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="2"/>
                    <count group_id="O13" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.821" spread="16.5047"/>
                    <measurement group_id="O2" value="7.18" spread="0"/>
                    <measurement group_id="O3" value="17.95" spread="0"/>
                    <measurement group_id="O5" value="9.25" spread="0"/>
                    <measurement group_id="O6" value="19.7" spread="0"/>
                    <measurement group_id="O8" value="5.328" spread="1.2794"/>
                    <measurement group_id="O9" value="5.45" spread="0"/>
                    <measurement group_id="O11" value="4.803" spread="2.7599"/>
                    <measurement group_id="O12" value="11.199" spread="8.4334"/>
                    <measurement group_id="O13" value="67.750" spread="110.0873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>RAC: Accumulation Ratio for TAK-117 in the Dose Escalation Cohort</title>
        <description>Accumulation ratio was based on AUC(0-24) between Cycle 1 Day 24 and Cycle 1 Day 1 (e.g. AUC(0-24) [Cycle 1 Day 24]/ AUC(0-24) [Cycle1 Day 1].</description>
        <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Overall number of participants analyzed is the number of participants with evaluable data at both Days 1 and 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
            <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
            <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
            <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
            <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
            <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
            <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>RAC: Accumulation Ratio for TAK-117 in the Dose Escalation Cohort</title>
          <description>Accumulation ratio was based on AUC(0-24) between Cycle 1 Day 24 and Cycle 1 Day 1 (e.g. AUC(0-24) [Cycle 1 Day 24]/ AUC(0-24) [Cycle1 Day 1].</description>
          <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Overall number of participants analyzed is the number of participants with evaluable data at both Days 1 and 24.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="1"/>
                <count group_id="O11" value="9"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.965" spread="0.1423"/>
                    <measurement group_id="O2" value="1.33" spread="0"/>
                    <measurement group_id="O3" value="1.161" spread="0.2506"/>
                    <measurement group_id="O5" value="1.049" spread="0.9033"/>
                    <measurement group_id="O6" value="1.18" spread="0"/>
                    <measurement group_id="O7" value="2.007" spread="0.4766"/>
                    <measurement group_id="O8" value="2.687" spread="0.5700"/>
                    <measurement group_id="O9" value="1.748" spread="1.1575"/>
                    <measurement group_id="O10" value="0.91" spread="0"/>
                    <measurement group_id="O11" value="1.879" spread="1.5772"/>
                    <measurement group_id="O12" value="0.925" spread="0.6281"/>
                    <measurement group_id="O13" value="4.183" spread="5.8060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak to Trough Ratio After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort</title>
        <time_frame>Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
            <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
            <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
            <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
            <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
            <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
            <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak to Trough Ratio After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort</title>
          <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="13"/>
                    <count group_id="O12" value="6"/>
                    <count group_id="O13" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.138" spread="21.6013"/>
                    <measurement group_id="O2" value="8.845" spread="7.8516"/>
                    <measurement group_id="O3" value="2.551" spread="0.9673"/>
                    <measurement group_id="O4" value="2.676" spread="0.1635"/>
                    <measurement group_id="O5" value="4.373" spread="3.3285"/>
                    <measurement group_id="O6" value="3.93" spread="0"/>
                    <measurement group_id="O7" value="3.602" spread="0.8361"/>
                    <measurement group_id="O8" value="6.640" spread="7.3746"/>
                    <measurement group_id="O9" value="6.877" spread="8.8600"/>
                    <measurement group_id="O10" value="2.631" spread="0.5993"/>
                    <measurement group_id="O11" value="6.872" spread="8.3680"/>
                    <measurement group_id="O12" value="11.494" spread="10.9430"/>
                    <measurement group_id="O13" value="3.426" spread="2.3804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="9"/>
                    <count group_id="O12" value="4"/>
                    <count group_id="O13" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.023" spread="9.0435"/>
                    <measurement group_id="O2" value="11.256" spread="7.1426"/>
                    <measurement group_id="O3" value="2.294" spread="0.5975"/>
                    <measurement group_id="O5" value="20.124" spread="33.8991"/>
                    <measurement group_id="O6" value="3.931" spread="2.4369"/>
                    <measurement group_id="O7" value="3.464" spread="0.1399"/>
                    <measurement group_id="O8" value="54.242" spread="87.1445"/>
                    <measurement group_id="O9" value="11.832" spread="15.4766"/>
                    <measurement group_id="O10" value="1.96" spread="0"/>
                    <measurement group_id="O11" value="5.482" spread="6.7075"/>
                    <measurement group_id="O12" value="11.184" spread="8.0869"/>
                    <measurement group_id="O13" value="4.664" spread="3.9973"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion Cohort</title>
        <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion Cohort</title>
          <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 3, TAK-228 administered alone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.38" upper_limit="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 10, TAK-228 administered with TAK-117</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.983" lower_limit="0.42" upper_limit="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion Cohort</title>
        <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion Cohort</title>
          <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 3, TAK-228 administered alone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.02" spread="21.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 10, TAK-228 administered with TAK-117</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.99" spread="22.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-228 in DDI Expansion Cohort</title>
        <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-228 in DDI Expansion Cohort</title>
          <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 3, TAK-228 administered alone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.613" spread="123.9584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 10, TAK-228 administered with TAK-117</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390.307" spread="155.3378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Phase Elimination Half-life (T1/2) for TAK-228 in DDI Expansion Cohort</title>
        <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Elimination Half-life (T1/2) for TAK-228 in DDI Expansion Cohort</title>
          <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 3, TAK-228 administered alone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.823" spread="2.1608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 10, TAK-228 administered with TAK-117</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.546" spread="1.8351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-228 in DDI Expansion Cohort</title>
        <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled))</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-228 in DDI Expansion Cohort</title>
          <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
          <units>L/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 3, TAK-228 administered alone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.368" spread="10.9714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 10, TAK-228 administered with TAK-117</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.359" spread="11.3718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak to Trough Ratio for TAK-228 in DDI Expansion Cohort</title>
        <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak to Trough Ratio for TAK-228 in DDI Expansion Cohort</title>
          <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 3, TAK-228 administered alone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.982" spread="11.6286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 10, TAK-228 administered with TAK-117</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.931" spread="15.6395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion Cohort</title>
        <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion Cohort</title>
          <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 10, TAK-117 administered with TAK-228</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.033" lower_limit="0.50" upper_limit="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 17, TAK-117 administered alone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.983" lower_limit="0.50" upper_limit="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion Cohort</title>
        <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion Cohort</title>
          <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 10, TAK-117 administered with TAK-228</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5357.3" spread="2842.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 17, TAK-117 administered alone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5332.6" spread="2955.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-117 in DDI Expansion Cohort</title>
        <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-117 in DDI Expansion Cohort</title>
          <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 10, TAK-117 administered with TAK-228</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61148.949" spread="42799.7918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 17, TAK-117 administered alone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63975.156" spread="53764.5716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Phase Elimination Half-life (T1/2) for TAK-117 in DDI Expansion Cohort</title>
        <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Elimination Half-life (T1/2) for TAK-117 in DDI Expansion Cohort</title>
          <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 10, TAK-117 administered with TAK-228</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.420" spread="2.3635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 17, TAK-117 administered alone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.717" spread="2.3715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-117 in DDI Expansion Cohort</title>
        <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-117 in DDI Expansion Cohort</title>
          <population>PK population consisted of all participants enrolled in the study who received at least 1 dose of TAK-228 and TAK-117 and had sufficient concentration-time data to calculate 1 or more PK parameters. Number analyzed is the number of participants with evaluable data at the given time-point.</population>
          <units>L/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 10, TAK-117 administered with TAK-228</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.797" spread="18.0040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 17, TAK-117 administered alone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.134" spread="8.7741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak to Trough Ratio for TAK-117 in DDI Expansion Cohort</title>
        <time_frame>Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose</time_frame>
        <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak to Trough Ratio for TAK-117 in DDI Expansion Cohort</title>
          <population>PK DDI-evaluable population consisted of all participants from Expansion Phase with sufficient dosing and concentration-time PK data to reliably estimate PK parameters for statistical analyses of effect of TAK-228 on TAK-117 PK and effect of TAK-117 on TAK-228 PK. Number analyzed is number of participants with evaluable data at given time-point.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 10, TAK-117 administered with TAK-228</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.423" spread="7.423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 17, TAK-117 administered alone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.357" spread="44.3461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR) Based on Investigator's Assessment According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</title>
        <description>ORR defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 for target lesions and assessed by CT or MRI. CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter (LD) of target lesions. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since the treatment started.</description>
        <time_frame>Baseline, Days 22 up to Day 28 of Cycle and every even-numbered cycle until disease progression or EOS (Up to approximately 68 weeks)</time_frame>
        <population>Safety population consisted of all enrolled participants who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
            <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
            <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
            <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
            <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
            <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
            <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
          </group>
          <group group_id="O14">
            <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) Based on Investigator's Assessment According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</title>
          <description>ORR defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 for target lesions and assessed by CT or MRI. CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter (LD) of target lesions. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since the treatment started.</description>
          <population>Safety population consisted of all enrolled participants who received at least 1 dose of any study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="14"/>
                <count group_id="O14" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                    <measurement group_id="O12" value="0.0"/>
                    <measurement group_id="O13" value="0.0"/>
                    <measurement group_id="O14" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR)</title>
        <description>The DOR is defined as the time from the date of first documented response of CR/PR to the first documented progressive disease (PD), or censored at the last response assessment date that is SD or better for a participant that has not progressed. CR was defined as the disappearance of all target lesions and for non-target lesions, the disappearance of all non-target lesions and normalization of tumor marker level. PR was defined of at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions.</description>
        <time_frame>Baseline, Days 22 up to Day 28 of Cycle and every even-numbered cycle until disease progression or EOS (Up to approximately 68 weeks)</time_frame>
        <population>Safety population consisted of all enrolled participants who received at least 1 dose of any study drug. Data for this outcome measure is reported for the participants with objective response available.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
            <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
            <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
            <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
            <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
            <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
            <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
            <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
            <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
          </group>
          <group group_id="O14">
            <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled)</title>
            <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR)</title>
          <description>The DOR is defined as the time from the date of first documented response of CR/PR to the first documented progressive disease (PD), or censored at the last response assessment date that is SD or better for a participant that has not progressed. CR was defined as the disappearance of all target lesions and for non-target lesions, the disappearance of all non-target lesions and normalization of tumor marker level. PR was defined of at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions.</description>
          <population>Safety population consisted of all enrolled participants who received at least 1 dose of any study drug. Data for this outcome measure is reported for the participants with objective response available.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O14" value="92" lower_limit="1" upper_limit="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 30 days after the last dose of study drug (Up to approximately 68 weeks)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dose Escalation Treatment Arm A: Cohort 1A</title>
          <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 4 cycles (each cycle was 28 days), up to 16 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Dose Escalation Treatment Arm A: Cohort 2A</title>
          <description>TAK-228 4 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 100 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 3 cycles (each cycle was 28 days), up to 10.4 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Dose Escalation Treatment Arm A: Cohort 3A</title>
          <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 5 cycles (each cycle was 28 days), up to 21.0 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Dose Escalation Treatment Arm A: Cohort 3A (Milled)</title>
          <description>TAK-228 2 mg, capsule (milled), orally, once daily every day (QD), and TAK-117 200 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 2 cycles (each cycle was 28 days), up to 6.1 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Dose Escalation Treatment Arm A: Cohort 4A</title>
          <description>TAK-228 2 mg, capsule (unmilled), orally, once daily every day (QD), and TAK-117 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Dose Escalation Treatment Arm B: Cohort 1B</title>
          <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 23.4 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Dose Escalation Treatment Arm B: Cohort 2B</title>
          <description>TAK-228 3 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 6 cycles (each cycle was 28 days), up to 21.3 weeks.</description>
        </group>
        <group group_id="E8">
          <title>Dose Escalation Treatment Arm B: Cohort 3B</title>
          <description>TAK-228 6 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 5 cycles (each cycle was 28 days), up to 19.4 weeks.</description>
        </group>
        <group group_id="E9">
          <title>Dose Escalation Treatment Arm B: Cohort 3B (Milled)</title>
          <description>TAK-228 6 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 4 cycles (each cycle was 28 days), up to 15.4 weeks.</description>
        </group>
        <group group_id="E10">
          <title>Dose Escalation Treatment Arm B: Cohort 4B</title>
          <description>TAK-228 8 mg, capsule (unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 2 cycles (each cycle was 28 days), up to 7.4 weeks.</description>
        </group>
        <group group_id="E11">
          <title>Dose Escalation Treatment Arm B: Cohort 5B (Milled)</title>
          <description>TAK-228 4 mg, capsule (milled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to 38.7 weeks.</description>
        </group>
        <group group_id="E12">
          <title>Dose Escalation Treatment Arm C: Cohort 1C</title>
          <description>TAK-228 3 mg, capsule (unmilled), orally, once on MTuW QW, and TAK-117 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to 64.3 weeks.</description>
        </group>
        <group group_id="E13">
          <title>Dose Escalation Treatment Arm C: Cohort 2C (Milled)</title>
          <description>TAK-228 3 mg, capsule (milled), orally, once on MTuW QW, and TAK-117 300 mg, capsule, orally, once on MTuW QW for up to 11 cycles (each cycle was 28 days), up to 43.4 weeks.</description>
        </group>
        <group group_id="E14">
          <title>Drug-Drug Interaction (DDI) Expansion Cohort (Milled)</title>
          <description>TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version: 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <description>One treatment-emergent death occurred during treatment with DDI expansion cohort (milled) and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <description>One treatment-emergent death occurred during treatment with dose escalation treatment arm A: cohort 4A and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <description>One treatment-emergent death occurred during treatment with dose escalation treatment arm A: cohort 5B (milled) and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <description>One treatment-emergent death occurred during treatment with DDI expansion cohort (milled) and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Salivary gland cancer</sub_title>
                <description>One treatment-emergent death occurred during treatment with dose escalation treatment arm A: cohort 5B (milled) and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tumour fistulisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>One treatment-emergent death occurred during treatment with dose escalation treatment arm A: cohort 3A and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version: 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="19" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Septal Defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness Transitory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ear Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Visual Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Eye Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="11" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anal Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anorectal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tongue Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Early Satiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Face Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hernia Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infusion Site Extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Medical Device Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Puncture Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Temperature Intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Unevaluable Event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fungal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Puncture Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Disorder Postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Stoma Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin Abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Post Procedural Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Electrocardiogram Qt Prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood Albumin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood Cholesterol Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood Sodium Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscle Twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Restless Legs Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Speech Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vocal Cord Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Depressed Mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Libido Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bladder Spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary Hesitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Breast Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Breast Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Burning Sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Paranasal Sinus Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Laryngeal Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dermatitis Acneiform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Palmar-Plantar Erythrodysaesthesia Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Swelling Face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Acne Cystic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Leukoplakia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Onychalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain Of Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash Pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin Exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin Lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vena Cava Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takedaâs sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

